Methylphenidate Teva

Methylphenidate, the active ingredient in Methylphenidate Teva, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults by enhancing focus and reducing excessive daytime sleepiness.

GNH USA supplies Methylphenidate Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand through reliable logistics and dedicated customer support.

Methylphenidate is a central nervous system stimulant that modulates dopamine and norepinephrine pathways, thereby improving attention, reducing impulsivity, and enhancing wakefulness in disorders characterized by attention deficits and excessive daytime sleepiness.

- Attention deficit hyperactivity disorder (ADHD): helps children, adolescents, and adults achieve better concentration, decrease hyperactive behavior, and improve impulse control, facilitating academic performance and daily functioning. - Narcolepsy: alleviates excessive daytime sleepiness, reduces the frequency of sudden sleep attacks, and supports sustained wakefulness, thereby improving occupational and social activities.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or other heart rhythm disturbances. - Psychosis: emergence of hallucinations or delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Methylphenidate requires careful assessment and monitoring to ensure safe use. - Cardiovascular assessment: evaluate blood pressure and heart rate before initiating therapy. - Growth monitoring: regularly assess height and weight in pediatric patients. - Psychiatric evaluation: monitor for emergence of anxiety, agitation, or psychotic symptoms. - Drug abuse potential: avoid use in individuals with a history of substance misuse. - Concomitant MAO inhibitors: discontinue MAO inhibitors at least 14 days before starting methylphenidate. - Store at room temperature: keep in the original container, protect from moisture and heat.

Methylphenidate may interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Antihypertensive agents: may reduce the effectiveness of blood‑pressure control. - Antipsychotics: can diminish stimulant effect and increase side‑effect burden.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels. - Alcohol: can enhance central nervous system stimulation and increase adverse‑event risk.